Scribe Therapeutics files for NASDAQ IPO as gene-editing interest revives
As seen on the 24/7 Wall St. homepage on July 23, 2026.
Biotech gene editor signals market debut
Scribe Therapeutics registered for its IPO as the gene-editing biotech prepares to go public, tapping into a revival of investor appetite for precision medicine startups.
Continue ReadingShow less
Scribe Therapeutics, Inc. has filed a registration statement with the SEC, formally setting the stage for its debut on the NASDAQ under the proposed ticker SCTX. The filing marks the company's transition from a private gene-editing biotech into a publicly traded entity, a step that requires regulatory review before any shares can actually be sold to investors.
The move comes as investor appetite for precision medicine startups shows signs of renewed life, making the timing of Scribe's registration notable for the broader biotech IPO market. Deal size, share count, and pricing range have not yet been disclosed in the filing, meaning the company is still in the early stages of its public offering process.
Sponsored
_________________________________
What's Your Number...?
Here's a question most people 5y from retirement can't answer: at your current savings rate, how much do you need, and how long will it actually last? A good advisor can put a date on that in a single meeting. SmartAsset's free quiz matches you with up to three fiduciary advisors serving your area, so you can get YOUR retirement number now (sponsor)
__________________________________________
What to watch next is the amended S-1 or prospectus that will follow, which should reveal the number of shares being offered, an expected price range, and the underwriters backing the deal — details that will give investors a clearer picture of the valuation Scribe is targeting.
Mentioned: SCTX